Otros idiomas LigaChem Biosciences Inc.

Acciones

A141080

KR7141080002

Precio de cierre Korea S.E. Otros sitios de cotización 00:00:00 28/06/2024			Varia. Cinco días.	Varia. 1 de enero.
71.200 ^KRW	-0,84 %		-1,79 %	+9,54 %

16/05	LigaChem Biosciences Inc. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI
08/04	NextCure, Inc. y LigaChem Biosciences, Inc. presentan en AACR 2024 datos preclínicos sobre un conjugado de fármacos contra el anticuerpo B7-H4	CI

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

LigaChem Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05
NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024	08/04
Pan Orion Corp. Ltd. completed the acquisition of 4.93% stake in LegoChem Biosciences, Inc. from Kim Yong Ju and Park Se Jin.	29/03
LigaChem Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Samsung Biologics Collaborates with LegoChem Biosciences on ADC Development and Manufacturing	09/02
Samsung Biologics partners with LegoChem Biosciences for ADC development and manufacturing	08/02
Orion Set to Acquire 25% Stake in LegoChem Biosciences	17/01
South Korean Shares Close Lower Amid Geopolitical Tension	16/01
Legochem Biosciences to Raise 469.8 Billion Won through Rights Issue; Shares Fall 5%	16/01
LegoChem Biosciences, Inc. announced that it expects to receive KRW 1018.327793998 billion in funding from Pan Orion Corp. Ltd.	15/01
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.	28/12
LegoChem Biosciences, Inc.'s Equity Buyback announced on June 28, 2023, has expired with 140,000 shares, representing 0.53% for KRW 4,879.08 million.	28/12
J&J : accord de licence avec le coréen LegoChem dans les ADC	27/12
Legochem Biosciences Announces License Agreement for Lcb84 Trop2-Targeted ADC	26/12
A little bit bad feels good	28/11
LegoChem Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
LegoChem Biosciences Selects BostonGene as Genomic Partner for First-in-Human Clinical Trial	08/11
BostonGene and LegoChem Biosciences, Inc. Announce Collaboration to Support Phase I/II Study of LCB84, TROP2-Directed ADC, in Patients with Advanced Cancers	07/11
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.	04/10/23
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.	04/10/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas LigaChem Biosciences Inc.

Acciones

A141080

KR7141080002

Otros idiomas

Filtros